search
Back to results

Working Toward the Advancement of Recovery Using Modulated Therapeutic Hyperthermia (WARMTH) in Sepsis - Pilot (WARMTH)

Primary Purpose

Sepsis

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Multimodal therapeutic warming w/ esophageal d/c
Multimodal therapeutic warming w/ conductive d/c
Sponsored by
Nicholas M Mohr
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sepsis focused on measuring hyperthermia, fever, sepsis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients above the age of 18 years old.
  • Patients with sepsis diagnosed within 48 hours of enrollment. For the purpose of this protocol, sepsis onset is defined as administration of intravenous antibiotics in a patient that the treating critical care physician feels is ill from sepsis.
  • All qualifying patients must have a sequential organ failure assessment (SOFA) score of 2 or greater at the time of enrollment.
  • Patients requiring mechanical ventilation with an expected duration of mechanical ventilation of >= 2 days.
  • Patient maximum baseline documented temperature (within previous 24 hours) < 38.3°C.

Exclusion Criteria:

  • Patients without legally authorized representative able to provide informed consent.
  • Patients with contraindication to core warming using an esophageal core warming device, surface warming using conductive heat transfer, and forced air warmer.
  • Patients known to be pregnant.
  • Patients with <40 kg of body mass.
  • Patients with comfort care only status.
  • Patients with contraindications to hyperthermia treatment (acute stroke, acute traumatic brain injury, acute spinal cord injury, post-cardiac arrest, multiple sclerosis, or sickle cell disease).
  • Expected continuous dialysis within 48 hours after enrollment.

Sites / Locations

  • University of Iowa Hospitals and Clinics
  • Hennepin County Medical Center
  • Washington University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Conductive Wrap Warming

Esophageal Warming

Arm Description

Esophageal warming will be discontinued first

Conductive wraps will be discontinued first

Outcomes

Primary Outcome Measures

Feasibility of warming critically ill patients with sepsis using a multimodal sepsis warming protocol.
Our primary outcome is the proportion of patients who achieve goal temperature within 6 hours of starting warming. After discontinuing devices, we will monitor the proportion of participants who remain at the goal temperature. Warming will be performed using standard technique per instructions for use for the surface warming wraps, esophageal heat transfer device, and forced air warming device. The heat exchanger will be set to a target patient temperature of 39°C, with patient temperature measured via temperature sensing Foley catheter or rectal temperature sensor. Feedback (servo) control is provided by the heat exchanger (Blanketrol III, Gentherm Medical, Cincinnati, OH), such that the water temperature flow through the warming devices is adjusted automatically to enable attainment of the target temperature. Forced air warming will be used until goal temperature is reached for at least 2 hours, then other devices will be used to maintain temperature.

Secondary Outcome Measures

Determine the rate of temperature change of patients undergoing a sepsis warming protocol.
Participants will be initiated on a warming protocol with forced air warming, surface conductive, and esophageal core warming with the target temperature of 39°C. Patient temperature measurement will be collected hourly during the study period (36 hours).
Determine the ability of conductive heat wraps vs. conductive esophageal device to maintain therapeutic hyperthermia
Once goal temperature has been achieved for 2 consecutive hours, the forced air warming device will be discontinued. Participants will be randomized at this point to Group 1, in which esophageal warming will be discontinued first or to Group 2, in which external conductive warming will be discontinued first. Once goal temperature has been achieved for 4 consecutive hours after discontinuation of the forced air warming device, the second device will be discontinued. If patient body temperature drops below goal temperature, the second warming device will be restarted to maintain temperature.

Full Information

First Posted
June 25, 2021
Last Updated
November 8, 2022
Sponsor
Nicholas M Mohr
Collaborators
Hennepin County Medical Center, Minneapolis, Washington University School of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT04961151
Brief Title
Working Toward the Advancement of Recovery Using Modulated Therapeutic Hyperthermia (WARMTH) in Sepsis - Pilot
Acronym
WARMTH
Official Title
Working Toward the Advancement of Recovery Using Modulated Therapeutic Hyperthermia (WARMTH) in Sepsis - Pilot
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Withdrawn
Why Stopped
Low enrollment
Study Start Date
August 25, 2021 (Actual)
Primary Completion Date
July 1, 2022 (Actual)
Study Completion Date
July 1, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Nicholas M Mohr
Collaborators
Hennepin County Medical Center, Minneapolis, Washington University School of Medicine

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this pilot study is to demonstrate the ability to warm critically ill patients with sepsis to a target temperature of 39°C
Detailed Description
Participants with sepsis and without fever will be warmed with surface (forced air and conductive wraps) and core (esophageal) warming, and will have the warming devices placed in the ICU. The warming devices will remain in place until the study is completed (36 hours). The heat exchangers will be set to attain a patient target temperature of 39°C as rapidly as possible, after which the forced-air (non-servo) system will be removed, and the conductive system heat exchanger (powering the water blankets and esophageal device, both of which are servo-controlled) will be set to maintain patient temperature at 39°C for the duration of the study period. Once goal temperature has been achieved for 2 consecutive hours, the forced air warming device will be discontinued. Patients will be randomized at this point to Group 1, in which esophageal warming will be discontinued first or to Group 2, in which external conductive warming will be discontinued first. All patients will have usual standard of care labs, vital signs, and imaging for patients undergoing mechanical ventilation in the ICU. For the duration of the 36-hour intervention, patient vital signs, including blood pressure, heart rate, respiratory rate, and vasopressor requirements will be monitored and recorded every 6 hours. Core temperature will be measured and recorded hourly. Patient's clinical status and outcome will be reviewed in the medical chart 7 days after study completion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
Keywords
hyperthermia, fever, sepsis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Conductive Wrap Warming
Arm Type
Experimental
Arm Description
Esophageal warming will be discontinued first
Arm Title
Esophageal Warming
Arm Type
Experimental
Arm Description
Conductive wraps will be discontinued first
Intervention Type
Other
Intervention Name(s)
Multimodal therapeutic warming w/ esophageal d/c
Intervention Description
In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, esophageal warming will be discontinued.
Intervention Type
Other
Intervention Name(s)
Multimodal therapeutic warming w/ conductive d/c
Intervention Description
In order to evaluate the ability to reliably raise patient temperature to a target of 39.0°C, patients will be warmed with forced air warming, surface conductive warming, and esophageal core warming. After 4 hours at target temperature, conductive warming will be discontinued.
Primary Outcome Measure Information:
Title
Feasibility of warming critically ill patients with sepsis using a multimodal sepsis warming protocol.
Description
Our primary outcome is the proportion of patients who achieve goal temperature within 6 hours of starting warming. After discontinuing devices, we will monitor the proportion of participants who remain at the goal temperature. Warming will be performed using standard technique per instructions for use for the surface warming wraps, esophageal heat transfer device, and forced air warming device. The heat exchanger will be set to a target patient temperature of 39°C, with patient temperature measured via temperature sensing Foley catheter or rectal temperature sensor. Feedback (servo) control is provided by the heat exchanger (Blanketrol III, Gentherm Medical, Cincinnati, OH), such that the water temperature flow through the warming devices is adjusted automatically to enable attainment of the target temperature. Forced air warming will be used until goal temperature is reached for at least 2 hours, then other devices will be used to maintain temperature.
Time Frame
36 hours
Secondary Outcome Measure Information:
Title
Determine the rate of temperature change of patients undergoing a sepsis warming protocol.
Description
Participants will be initiated on a warming protocol with forced air warming, surface conductive, and esophageal core warming with the target temperature of 39°C. Patient temperature measurement will be collected hourly during the study period (36 hours).
Time Frame
36 hours
Title
Determine the ability of conductive heat wraps vs. conductive esophageal device to maintain therapeutic hyperthermia
Description
Once goal temperature has been achieved for 2 consecutive hours, the forced air warming device will be discontinued. Participants will be randomized at this point to Group 1, in which esophageal warming will be discontinued first or to Group 2, in which external conductive warming will be discontinued first. Once goal temperature has been achieved for 4 consecutive hours after discontinuation of the forced air warming device, the second device will be discontinued. If patient body temperature drops below goal temperature, the second warming device will be restarted to maintain temperature.
Time Frame
36 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients above the age of 18 years old. Patients with sepsis diagnosed within 48 hours of enrollment. For the purpose of this protocol, sepsis onset is defined as administration of intravenous antibiotics in a patient that the treating critical care physician feels is ill from sepsis. All qualifying patients must have a sequential organ failure assessment (SOFA) score of 2 or greater at the time of enrollment. Patients requiring mechanical ventilation with an expected duration of mechanical ventilation of >= 2 days. Patient maximum baseline documented temperature (within previous 24 hours) < 38.3°C. Exclusion Criteria: Patients without legally authorized representative able to provide informed consent. Patients with contraindication to core warming using an esophageal core warming device, surface warming using conductive heat transfer, and forced air warmer. Patients known to be pregnant. Patients with <40 kg of body mass. Patients with comfort care only status. Patients with contraindications to hyperthermia treatment (acute stroke, acute traumatic brain injury, acute spinal cord injury, post-cardiac arrest, multiple sclerosis, or sickle cell disease). Expected continuous dialysis within 48 hours after enrollment.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicholas Mohr, MD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Iowa Hospitals and Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Facility Name
Hennepin County Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55415
Country
United States
Facility Name
Washington University
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63130
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Working Toward the Advancement of Recovery Using Modulated Therapeutic Hyperthermia (WARMTH) in Sepsis - Pilot

We'll reach out to this number within 24 hrs